Cyclacel Pharmaceuticals

$4.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+1.02%) As of 1:57 PM EDT today

Why Robinhood?

You can buy or sell CYCC and other stocks, options, and ETFs commission-free!

About CYCC

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ. The listed name for CYCC is Cyclacel Pharmaceuticals, Inc. Common Stock.

Employees
12
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
19.94M
Price-Earnings Ratio
Dividend Yield
Average Volume
171.45K
High Today
$4.15
Low Today
$4.00
Open Price
$4.06
Volume
62.20K
52 Week High
$19.60
52 Week Low
$3.19

Collections

CYCC Earnings

-$2.90
-$1.93
-$0.97
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 12, After Hours

You May Also Like